Cubist Systematic Strategies’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Cubist Systematic Strategies’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-16,495	Closed	-$55.4K	–	4386
2023 Q4	$55.4K	Buy	16,495 +2,789	+20%	+$7.18K	﹤0.01%	3262
2023 Q3	$32.6K	Sell	13,706 -38,043	-74%	-$79.7K	﹤0.01%	3060
2023 Q2	$91.1K	Sell	51,749 -240,972	-82%	-$616K	﹤0.01%	3009
2023 Q1	$902K	Buy	292,721 +207,178	+242%	+$1.24M	0.01%	2260
2022 Q4	$453K	Buy	85,543 +70,033	+452%	+$320K	﹤0.01%	3093
2022 Q3	$55K	Buy	+15,510	New	+$51.3K	﹤0.01%	4116
2022 Q1	–	Sell	-23,432	Closed	-$160K	–	3819
2021 Q4	$160K	Buy	+23,432	New	+$160K	﹤0.01%	3097

Other funds holding PSTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Cubist Systematic Strategies's PSTX Position: Q1 2024 in Review

Cubist Systematic Strategies sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2024, closing a stake of 16,495 shares — an estimated $55.4K sold.

Cubist Systematic Strategies first reported a position in PSTX in Q4 2021 and held it in 7 quarters. The position peaked at $902K in Q1 2023. 91 funds tracked by Wall St. Rank hold PSTX as of Q1 2024.

Cubist Systematic Strategies reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Cubist Systematic Strategies sold 16,495 Poseida Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $55.4K.
Cubist Systematic Strategies first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
Cubist Systematic Strategies's Poseida Therapeutics, Inc. Common Stock position peaked at $902K in Q1 2023.
91 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Cubist Systematic Strategies's 13F filing for Q1 2024, filed 15 May 2024.